Valuation: Positron Corporation

Market Cap 55.9M 50.06M 46.05M 41.72M 77.99M 5.31B 79.45M 549M 220M 2.79B 210M 205M 8.8B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 54.76M 49.05M 45.11M 40.88M 76.41M 5.2B 77.84M 538M 216M 2.74B 206M 201M 8.63B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
45.36%
Yield 2024 *
-
Yield 2025 -
1 day+0.11%
1 week+1.61%
Current month-4.82%
1 month-4.82%
3 months+1.91%
6 months-4.92%
Current year+1.91%
1 week 1.57
Extreme 1.57
1.73
1 month 1.43
Extreme 1.43
1.94
Current year 1.43
Extreme 1.43
2.74
1 year 1.27
Extreme 1.27
2.74
3 years 0.87
Extreme 0.87
2.94
5 years 0.07
Extreme 0.0682
2.94
10 years 0
Extreme 0
2.94
Manager TitleAgeSince
President 53 2018-02-26
Sales & Marketing - 2022-06-23
Corporate Officer/Principal 40 2018-05-24
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+0.11%+1.61%+6.37%+36.15% 55.9M
-1.72%+3.44%+25.31%+60.56% 258B
-2.00%+0.75%+7.99%+25.46% 163B
-3.73%-4.48%-18.49%+67.13% 150B
-1.66%-8.12%-58.26%-16.12% 60.84B
-2.57%+3.30%+10.22%+47.55% 53.03B
0.00%+2.46%-11.97%-6.29% 53.31B
-3.47%+1.04%+21.98%+72.85% 49.3B
+0.84%-3.12%+9.80%+64.47% 50.67B
-3.61%+1.99%+34.94%+95.49% 45.46B
Average -1.78%-0.11%+2.79%+44.72% 88.35B
Weighted average by Cap. -2.10%+0.15%+5.19%+47.79%

Financials

2024 2025
Net sales 588K 526K 484K 439K 820K 55.78M 835K 5.77M 2.32M 29.34M 2.2M 2.16M 92.54M 461K 413K 380K 344K 644K 43.82M 656K 4.53M 1.82M 23.05M 1.73M 1.69M 72.69M
Net income -2.38M -2.13M -1.96M -1.78M -3.32M -226M -3.38M -23.37M -9.38M -119M -8.93M -8.74M -375M -10.6M -9.5M -8.74M -7.91M -14.79M -1.01B -15.07M -104M -41.82M -530M -39.79M -38.95M -1.67B
Net Debt 1.42M 1.28M 1.17M 1.06M 1.99M 135M 2.02M 13.99M 5.62M 71.14M 5.35M 5.23M 224M -1.14M -1.02M -936K -848K -1.59M -108M -1.61M -11.16M -4.48M -56.75M -4.26M -4.17M -179M
Projected Income Statement - Annual - Positron Corporation
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
10
Date Price Change Volume
26-10-30 $1.702 +0.11% 4,950
26-10-29 $1.700 -1.16% 10,025
26-10-27 $1.720 +1.18% 13,651
26-10-26 $1.700 +1.49% 215
26-10-23 $1.675 +2.76% 110
  1. Stock Market
  2. Stocks
  3. POSC Stock